Literature DB >> 20065056

GES-13, a beta-lactamase variant possessing Lys-104 and Asn-170 in Pseudomonas aeruginosa.

S D Kotsakis1, C C Papagiannitsis, E Tzelepi, N J Legakis, V Miriagou, L S Tzouvelekis.   

Abstract

GES-13 beta-lactamase, a novel GES variant possessing Lys-104 and Asn-170, was identified in Pseudomonas aeruginosa. bla(GES-13) was the single gene cassette of a class 1 integron probably located in the chromosome. GES-13 efficiently hydrolyzed broad-spectrum cephalosporins and aztreonam. Imipenem was a potent inhibitor of GES-13 but was not hydrolyzed at measurable rates.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20065056      PMCID： PMC2825989          DOI： 10.1128/AAC.01561-09

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  16 in total

1.  An integron-associated beta-lactamase (IBC-2) from Pseudomonas aeruginosa is a variant of the extended-spectrum beta-lactamase IBC-1.

Authors:  A Mavroidi; E Tzelepi; A Tsakris; V Miriagou; D Sofianou; L S Tzouvelekis
Journal:  J Antimicrob Chemother       Date:  2001-11       Impact factor: 5.790

2.  IBC-1, a novel integron-associated class A beta-lactamase with extended-spectrum properties produced by an Enterobacter cloacae clinical strain.

Authors:  P Giakkoupi; L S Tzouvelekis; A Tsakris; V Loukova; D Sofianou; E Tzelepi
Journal:  Antimicrob Agents Chemother       Date:  2000-09       Impact factor: 5.191

3.  Integron-encoded GES-type extended-spectrum beta-lactamase with increased activity toward aztreonam in Pseudomonas aeruginosa.

Authors:  Laurent Poirel; Laura Brinas; Nicolas Fortineau; Patrice Nordmann
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

4.  Rapid procedure for detection and isolation of large and small plasmids.

Authors:  C I Kado; S T Liu
Journal:  J Bacteriol       Date:  1981-03       Impact factor: 3.490

5.  GES-2, a class A beta-lactamase from Pseudomonas aeruginosa with increased hydrolysis of imipenem.

Authors:  L Poirel; G F Weldhagen; T Naas; C De Champs; M G Dove; P Nordmann
Journal:  Antimicrob Agents Chemother       Date:  2001-09       Impact factor: 5.191

6.  Molecular characterization of a cephamycin-hydrolyzing and inhibitor-resistant class A beta-lactamase, GES-4, possessing a single G170S substitution in the omega-loop.

Authors:  Jun-ichi Wachino; Yohei Doi; Kunikazu Yamane; Naohiro Shibata; Tetsuya Yagi; Takako Kubota; Yoshichika Arakawa
Journal:  Antimicrob Agents Chemother       Date:  2004-08       Impact factor: 5.191

7.  Novel GES/IBC extended-spectrum beta-lactamase variants with carbapenemase activity in clinical enterobacteria.

Authors:  Sofia Vourli; Panagiota Giakkoupi; Vivi Miriagou; Eva Tzelepi; Alkiviadis C Vatopoulos; Leonidas S Tzouvelekis
Journal:  FEMS Microbiol Lett       Date:  2004-05-15       Impact factor: 2.742

8.  GES-11, a novel integron-associated GES variant in Acinetobacter baumannii.

Authors:  Carole Moubareck; Sylvie Brémont; Marie-Christine Conroy; Patrice Courvalin; Thierry Lambert
Journal:  Antimicrob Agents Chemother       Date:  2009-05-18       Impact factor: 5.191

9.  Nosocomial spread of ceftazidime-resistant Klebsiella pneumoniae strains producing a novel class a beta-lactamase, GES-3, in a neonatal intensive care unit in Japan.

Authors:  Jun-ichi Wachino; Yohei Doi; Kunikazu Yamane; Naohiro Shibata; Tetsuya Yagi; Takako Kubota; Hideo Ito; Yoshichika Arakawa
Journal:  Antimicrob Agents Chemother       Date:  2004-06       Impact factor: 5.191

10.  Relative strengths of the class 1 integron promoter hybrid 2 and the combinations of strong and hybrid 1 with an active p2 promoter.

Authors:  Costas C Papagiannitsis; Leonidas S Tzouvelekis; Vivi Miriagou
Journal:  Antimicrob Agents Chemother       Date:  2008-11-10       Impact factor: 5.191
View more
  10 in total

1.  In vitro selection of variants resistant to beta-lactams plus beta-lactamase inhibitors in CTX-M beta-lactamases: predicting the in vivo scenario?

Authors:  Aida Ripoll; Fernando Baquero; Angela Novais; Mario J Rodríguez-Domínguez; Maria-Carmen Turrientes; Rafael Cantón; Juan-Carlos Galán
Journal:  Antimicrob Agents Chemother       Date:  2011-07-25       Impact factor: 5.191

2.  In vitro prediction of the evolution of GES-1 β-lactamase hydrolytic activity.

Authors:  Séverine Bontron; Laurent Poirel; Patrice Nordmann
Journal:  Antimicrob Agents Chemother       Date:  2015-01-05       Impact factor: 5.191

3.  Importance of position 170 in the inhibition of GES-type β-lactamases by clavulanic acid.

Authors:  Hilary Frase; Marta Toth; Matthew M Champion; Nuno T Antunes; Sergei B Vakulenko
Journal:  Antimicrob Agents Chemother       Date:  2011-01-10       Impact factor: 5.191

4.  Comparative biochemical and computational study of the role of naturally occurring mutations at Ambler positions 104 and 170 in GES β-lactamases.

Authors:  Stathis D Kotsakis; Vivi Miriagou; Eva Tzelepi; Leonidas S Tzouvelekis
Journal:  Antimicrob Agents Chemother       Date:  2010-08-09       Impact factor: 5.191

5.  Molecular Characterization of Carbapenemase-Producing Pseudomonas aeruginosa of Czech Origin and Evidence for Clonal Spread of Extensively Resistant Sequence Type 357 Expressing IMP-7 Metallo-β-Lactamase.

Authors:  Costas C Papagiannitsis; Matej Medvecky; Katerina Chudejova; Anna Skalova; Veronika Rotova; Petra Spanelova; Vladislav Jakubu; Helena Zemlickova; Jaroslav Hrabak
Journal:  Antimicrob Agents Chemother       Date:  2017-11-22       Impact factor: 5.191

6.  GES-18, a new carbapenem-hydrolyzing GES-Type β-lactamase from Pseudomonas aeruginosa that contains Ile80 and Ser170 residues.

Authors:  Carine Bebrone; Pierre Bogaerts; Heinrich Delbrück; Sandra Bennink; Michaël B Kupper; Roberta Rezende de Castro; Youri Glupczynski; Kurt M Hoffmann
Journal:  Antimicrob Agents Chemother       Date:  2012-10-31       Impact factor: 5.191

7.  Pseudomonas aeruginosa: resistance to the max.

Authors:  Keith Poole
Journal:  Front Microbiol       Date:  2011-04-05       Impact factor: 5.640

8.  Prevalence of ESBL-producing Pseudomonas aeruginosa isolates in Warsaw, Poland, detected by various phenotypic and genotypic methods.

Authors:  Agnieszka E Laudy; Patrycja Róg; Katarzyna Smolińska-Król; Milena Ćmiel; Alicja Słoczyńska; Jan Patzer; Danuta Dzierżanowska; Renata Wolinowska; Bohdan Starościak; Stefan Tyski
Journal:  PLoS One       Date:  2017-06-28       Impact factor: 3.240

9.  Novel Insights into blaGES Mobilome Reveal Extensive Genetic Variation in Hospital Effluents.

Authors:  Danieli Conte; Dany Mesa; Thomas Jové; Caetana Paes Zamparette; Thaís Cristine Marques Sincero; Jussara Kasuko Palmeiro; Libera Maria Dalla-Costa
Journal:  Microbiol Spectr       Date:  2022-07-26

10.  Osteomyelitis due to multiple carbapenemase-producing Gram-negative bacteria: The first case report of a GES-13-producing Pseudomonas aeruginosa isolate in Canada.

Authors:  Shadi Sepehri; Guillaume Poliquin; Nora Alfattoh; David Boyd; Michael Mulvey; Andrew Denisuik; Sergio Fanella; James Karlowsky; Andrew Walkty
Journal:  Can J Infect Dis Med Microbiol       Date:  2014-07       Impact factor: 2.471
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.